RT Journal Article
SR Electronic
T1 OSK-0028 in Patients With Esophageal Cancer Undergoing Esophagectomy: A Double-blind, Randomised Controlled Trial
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3875
OP 3884
DO 10.21873/anticanres.15182
VO 41
IS 8
A1 KOTARO YAMASHITA
A1 YASUHIRO MIYAZAKI
A1 DAISAKU NAKATANI
A1 YASUNORI MASUIKE
A1 KOJI TANAKA
A1 KEIJIRO SUGIMURA
A1 TOMOKI MAKINO
A1 OSAMU SHIRAISHI
A1 TSUYOSHI TAKAHASHI
A1 YUKINORI KUROKAWA
A1 MAKOTO YAMASAKI
A1 HIROSHI MIYATA
A1 YUTAKA KIMURA
A1 HIROYUKI ARAKI
A1 TOMOMI YAMADA
A1 TAKUSHI YASUDA
A1 MASAHIKO YANO
A1 HIDETOSHI EGUCHI
A1 YUICHIRO DOKI
YR 2021
UL http://ar.iiarjournals.org/content/41/8/3875.abstract
AB Background/Aim: An excessive postoperative inflammatory response is correlated with the development of pneumonia and an unfavourable prognosis in patients undergoing esophagectomy for esophageal cancer. We assessed the influence of OSK-0028, a synthetic human ghrelin on inflammatory response and energy metabolism, on the postoperative course of patients following radical esophagectomy. Patients and Methods: Esophageal cancer patients were randomly assigned to low-dose (LD; 0.25 μg/kg/h) or high-dose (HD; 0.5 μg/kg/h) intravenous OSK-0028 or placebo for 7 days after esophagectomy. The primary endpoint was serum interleukin-6 level on postoperative day (POD) 3. Results: A total of 75 patients were enrolled (23 LD, 26 HD, 26 placebo). The median interleukin-6 levels on POD 3 were 40.95, 35.85, and 64.50 pg/ml in the placebo, LD, and HD groups, respectively, with no significant differences (p=0.78). Postoperative complications did not differ between groups. Bodyweight loss was significantly lower in patients receiving OSK-0028 than in those receiving placebo (–0.17% vs. 1.78%, p=0.043). Conclusion: Although OSK-0028 did not attenuate inflammatory response after esophagectomy, it prevented postoperative bodyweight loss.